Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

BACKGROUND: The association between obesity and outcomes in patients receiving programmed death-1/programmed death ligand-1 (PD-L1) checkpoint inhibitors has already been confirmed in pre-treated non-small cell lung cancer (NSCLC) patients, regardless of PD-L1 tumor expression. METHODS: We present t...

詳細記述

保存先:
書誌詳細
出版年:J Immunother Cancer
主要な著者: Cortellini, Alessio, Ricciuti, Biagio, Tiseo, Marcello, Bria, Emilio, Banna, Giuseppe L, Aerts, Joachim GJV, Barbieri, Fausto, Giusti, Raffaele, Cortinovis, Diego L, Migliorino, Maria R, Catino, Annamaria, Passiglia, Francesco, Torniai, Mariangela, Morabito, Alessandro, Genova, Carlo, Mazzoni, Francesca, Di Noia, Vincenzo, Signorelli, Diego, Gelibter, Alain, Occhipinti, Mario Alberto, Rastelli, Francesca, Chiari, Rita, Rocco, Danilo, Inno, Alessandro, De Tursi, Michele, Di Marino, Pietro, Mansueto, Giovanni, Zoratto, Federica, Grossi, Francesco, Filetti, Marco, Pizzutilo, Pamela, Russano, Marco, Citarella, Fabrizio, Cantini, Luca, Targato, Giada, Nigro, Olga, Ferrara, Miriam G, Buti, Sebastiano, Scodes, Simona, Landi, Lorenza, Guaitoli, Giorgia, Della Gravara, Luigi, Tabbò, Fabrizio, Ricciardi, Serena, De Toma, Alessandro, Friedlaender, Alex, Petrelli, Fausto, Addeo, Alfredo, Porzio, Giampiero, Ficorella, Corrado
フォーマット: Artigo
言語:Inglês
出版事項: BMJ Publishing Group 2020
主題:
Clinical/Translational Cancer Immunotherapy
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7574933/
https://ncbi.nlm.nih.gov/pubmed/33077515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001403
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料